Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
Lorusso D, Ferrandina G, Pignata S, Ludovisi M, Viganò R, Scalone S, Scollo P, Breda E, Pietragalla A, Scambia G. Lorusso D, et al. Among authors: breda e. Ann Oncol. 2010 Jan;21(1):61-6. doi: 10.1093/annonc/mdp266. Epub 2009 Jul 15. Ann Oncol. 2010. PMID: 19605508 Free article. Clinical Trial.
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
Piccirillo MC, Scambia G, Bologna A, Signoriello S, Vergote I, Baumann K, Lorusso D, Murgia V, Sorio R, Ferrandina G, Sacco C, Cormio G, Breda E, Cinieri S, Natale D, Mangili G, Pisano C, Cecere SC, Di Napoli M, Salutari V, Raspagliesi F, Arenare L, Bergamini A, Bryce J, Daniele G, Gallo C, Pignata S, Perrone F. Piccirillo MC, et al. Among authors: breda e. Ann Oncol. 2018 May 1;29(5):1189-1194. doi: 10.1093/annonc/mdy062. Ann Oncol. 2018. PMID: 29462248 Free article. Clinical Trial.
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Lorusso D, Ferrandina G, Colombo N, Pignata S, Pietragalla A, Sonetto C, Pisano C, Lapresa MT, Savarese A, Tagliaferri P, Lombardi D, Cinieri S, Breda E, Sabatucci I, Sabbatini R, Conte C, Cecere SC, Maltese G, Scambia G. Lorusso D, et al. Among authors: breda e. Gynecol Oncol. 2019 Dec;155(3):406-412. doi: 10.1016/j.ygyno.2019.10.013. Epub 2019 Oct 31. Gynecol Oncol. 2019. PMID: 31677820 Clinical Trial.
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, Riva N, De Rosa V, Gallo C, Perrone F; Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group. Pignata S, et al. Among authors: breda e. Br J Cancer. 2007 Jun 4;96(11):1639-43. doi: 10.1038/sj.bjc.6603787. Epub 2007 May 8. Br J Cancer. 2007. PMID: 17486128 Free PMC article. Clinical Trial.
Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients.
Ferrandina G, Petrillo M, Carbone A, Zannoni G, Martinelli E, Prisco M, Pignata S, Breda E, Savarese A, Scambia G. Ferrandina G, et al. Among authors: breda e. Br J Cancer. 2008 Jun 17;98(12):1910-5. doi: 10.1038/sj.bjc.6604410. Epub 2008 May 27. Br J Cancer. 2008. PMID: 18506140 Free PMC article.
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S, Scambia G, Savarese A, Breda E, Sorio R, Pisano C, Lorusso D, Cognetti F, Vernaglia Lombardi A, Gebbia V, Scollo P, Morabito A, Signoriello G, Perrone F. Pignata S, et al. Among authors: breda e. Oncology. 2009;76(1):49-54. doi: 10.1159/000178760. Epub 2008 Nov 27. Oncology. 2009. PMID: 19039248 Clinical Trial.
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
Falcone F, Scambia G, Benedetti Panici P, Signorelli M, Cormio G, Giorda G, Bogliolo S, Marinaccio M, Ghezzi F, Rabaiotti E, Breda E, Casella G, Fanfani F, Di Donato V, Leone Roberti Maggiore U, Greggi S. Falcone F, et al. Among authors: breda e. Gynecol Oncol. 2017 Oct;147(1):66-72. doi: 10.1016/j.ygyno.2017.07.008. Epub 2017 Jul 15. Gynecol Oncol. 2017. PMID: 28716306
Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: Results from the MITO-9 study.
Bergamini A, Ferrandina G, Candiani M, Cormio G, Giorda G, Lauria R, Perrone AM, Scarfone G, Breda E, Savarese A, Frigerio L, Gadducci A, Mascilini F, Maneschi F, Cassani C, Marchetti C, Cecere SC, Biglia N, De Giorgi U, Raspagliesi F, Lorusso D, Mangili G. Bergamini A, et al. Among authors: breda e. Eur J Surg Oncol. 2018 Jun;44(6):766-770. doi: 10.1016/j.ejso.2018.03.001. Epub 2018 Mar 10. Eur J Surg Oncol. 2018. PMID: 29576462
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy.
Pignata S, Amant F, Scambia G, Sorio R, Breda E, Rasch W, Hernes K, Pisano C, Leunen K, Lorusso D, Cannella L, Vergote I. Pignata S, et al. Among authors: breda e. Cancer Chemother Pharmacol. 2011 Nov;68(5):1347-53. doi: 10.1007/s00280-011-1735-4. Epub 2011 Sep 10. Cancer Chemother Pharmacol. 2011. PMID: 21909644 Clinical Trial.
172 results